Crit Care:脓毒症患者视网膜动脉血流及视网膜改变!

2017-04-11 xing.T MedSci原创

由此可见,延长RAFT的患者视网膜血管成像变化更加频繁和心脏指数更低,而填充时间较短的患者炎症标志物水平较高。

虽然脓毒症患者组织灌注通常有所降低,但对大循环血流动力学和微循环血流量之间的关系了解甚少。近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,研究人员假设通过血管成像可视化的视网膜血流量变化可能与大循环血流动力学、炎症介质以及视网膜微循环改变相关。

研究人员对脓毒症患者入住ICU的前5天内进行2次视网膜荧光血管造影来观察视网膜病变。视网膜的改变是通过强荧光血管造影来证实;通过视网膜动脉充盈时间(RAFT)来测量视网膜血流量;并且对眼压进行了测定。研究人员收集了血液样本中炎症和脑生物标志物,并且对大循环血流动力学指标进行了监测。RAFT如果超过8.3 秒则被归类为延长的RAFT。

在31例患者中,29名(93%)患者为感染性休克,30名(97%)患者需要机械通气,22名(71%)患者发生谵妄,16名(51.6%)患者有视网膜病变,其中75%的患者为双侧病变。存在延长RAFT的患者在血管造影前(2.1 L/kg/m2 vs. 3.1 L/kg/m2, P=0.042)和期间(2.1 L/kg/m2 vs. 2.6 L/kg/m2, P=0.039)有较低的心脏指数。他们发生视网膜病变的频率更高(81% vs. 20%,P=0.001),并眼压更高(18mmHg vs. 14mmHg,P=0.031)。延长RAFT的患者的C-反应蛋白(139mg/L vs. 254mg/L,P=0.011)和白细胞介素-6(39pg/ml vs. 101pg/ml,P<0.001)较低,相比于那些RAFT较短的患者。

由此可见,延长RAFT的患者视网膜血管成像变化更加频繁和心脏指数更低,而填充时间较短的患者炎症标志物水平较高。

原始出处:

Kristo Erikson, et al. Retinal arterial blood flow and retinal changes in patients with sepsis: preliminary study using fluorescein angiography.Critical Care.2017. https://ccforum.biomedcentral.com/articles/10.1186/s13054-017-1676-3

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2040565, encodeId=84d32040565d1, content=<a href='/topic/show?id=01223333623' target=_blank style='color:#2F92EE;'>#动脉血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33336, encryptionId=01223333623, topicName=动脉血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Fri Aug 04 08:53:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708965, encodeId=9e681e0896580, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sat Jul 22 16:53:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187265, encodeId=9bc518e265ff, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Apr 14 07:46:37 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269864, encodeId=2a68126986486, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516347, encodeId=c5cf151634ef9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186725, encodeId=a728186e25d5, content=一天不来,好大的变化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Apr 11 20:02:07 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2040565, encodeId=84d32040565d1, content=<a href='/topic/show?id=01223333623' target=_blank style='color:#2F92EE;'>#动脉血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33336, encryptionId=01223333623, topicName=动脉血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Fri Aug 04 08:53:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708965, encodeId=9e681e0896580, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sat Jul 22 16:53:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187265, encodeId=9bc518e265ff, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Apr 14 07:46:37 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269864, encodeId=2a68126986486, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516347, encodeId=c5cf151634ef9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186725, encodeId=a728186e25d5, content=一天不来,好大的变化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Apr 11 20:02:07 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2040565, encodeId=84d32040565d1, content=<a href='/topic/show?id=01223333623' target=_blank style='color:#2F92EE;'>#动脉血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33336, encryptionId=01223333623, topicName=动脉血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Fri Aug 04 08:53:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708965, encodeId=9e681e0896580, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sat Jul 22 16:53:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187265, encodeId=9bc518e265ff, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Apr 14 07:46:37 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269864, encodeId=2a68126986486, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516347, encodeId=c5cf151634ef9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186725, encodeId=a728186e25d5, content=一天不来,好大的变化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Apr 11 20:02:07 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
    2017-04-14 ylzr123

    不错的方式,努力学习,刻苦专研,不断总结出来新经验。不错的方式,努力学习,刻苦专研,不断总结出来新经验。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2040565, encodeId=84d32040565d1, content=<a href='/topic/show?id=01223333623' target=_blank style='color:#2F92EE;'>#动脉血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33336, encryptionId=01223333623, topicName=动脉血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Fri Aug 04 08:53:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708965, encodeId=9e681e0896580, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sat Jul 22 16:53:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187265, encodeId=9bc518e265ff, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Apr 14 07:46:37 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269864, encodeId=2a68126986486, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516347, encodeId=c5cf151634ef9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186725, encodeId=a728186e25d5, content=一天不来,好大的变化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Apr 11 20:02:07 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
    2017-04-13 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=2040565, encodeId=84d32040565d1, content=<a href='/topic/show?id=01223333623' target=_blank style='color:#2F92EE;'>#动脉血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33336, encryptionId=01223333623, topicName=动脉血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Fri Aug 04 08:53:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708965, encodeId=9e681e0896580, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sat Jul 22 16:53:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187265, encodeId=9bc518e265ff, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Apr 14 07:46:37 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269864, encodeId=2a68126986486, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516347, encodeId=c5cf151634ef9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186725, encodeId=a728186e25d5, content=一天不来,好大的变化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Apr 11 20:02:07 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2040565, encodeId=84d32040565d1, content=<a href='/topic/show?id=01223333623' target=_blank style='color:#2F92EE;'>#动脉血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33336, encryptionId=01223333623, topicName=动脉血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Fri Aug 04 08:53:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708965, encodeId=9e681e0896580, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sat Jul 22 16:53:00 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187265, encodeId=9bc518e265ff, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。不错的方式,努力学习,刻苦专研,不断总结出来新经验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Apr 14 07:46:37 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269864, encodeId=2a68126986486, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516347, encodeId=c5cf151634ef9, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Thu Apr 13 10:53:00 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186725, encodeId=a728186e25d5, content=一天不来,好大的变化!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Tue Apr 11 20:02:07 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
    2017-04-11 thlabcde

    一天不来,好大的变化!

    0

相关资讯

Am J Resp Crit Care:脓毒症中性粒细胞自噬早于胞外陷阱形成!

这些结果表明,中性粒细胞自噬早于中性粒细胞NETs形成增加,这对于败血症期间中性粒细胞效应功能非常重要。该研究为脓毒症期间中性粒细胞自噬的作用提供了重要的见解。

Crit Care Med:急诊科脓毒症患者抗菌药物治疗时间的差异分析!

在急诊室接受抗菌药物治疗的严重脓毒症或感染性休克患者中,治疗医生从患者进入诊室到进行抗菌药物治疗的时间有所不同,存在五倍的差异。由于抗生素治疗延迟和死亡率之间的相关性,降低医生抗菌治疗启动时间的干预措施可能是必要的。

JAMA:右美托咪定不能改善脓毒症通气患者的临床结局

需要机械通气的脓毒症患者中,使用右美托咪定的患者并显着改善患者的死亡率或呼吸机使用天数

Am J Resp Crit Care:脓毒症早期抗生素治疗时机与住院死亡率有啥关系?

在一个大型的、当代多中心的急诊科脓毒症患者的样本中,抗生素使用延误与住院死亡率的几率增加有关,即使在所有6小时内接受抗生素治疗的患者中。在感染性休克患者中脓毒症严重程度增加和死亡率增加的可能性最大。

Crit Care Med:ICU脓毒症患者:累积体液平衡较高或增加死亡风险

脓毒症患者过量的液体治疗风险或超过任何获益。2017年3月,发表在《Crit Care Med》的一项观察性队列研究表示,液体平衡较高或增加脓毒症患者死亡风险。目的:脓毒症患者过量的液体治疗风险或超过任何获益。在一项大型国际性的ICU脓毒症患者数据库中,研究者评估了早期液体平衡对ICU脓毒症患者临床结局的潜在影响。设计:观察性队列研究。地点:84个国家的730个ICUs。患者:除了术后常规监测外,

精品指南:愚人节不骗你,脓毒症和脓毒性休克指南干货来袭

    严重脓毒症、脓毒性休克相关性脏器功能障碍是引起重症监护病房患者死亡的最常见原因,尽管实施严密的脏器功能监护、早期积极的液体复苏、合理应用抗微生物制剂、有效的脏器功能支持,但严重脓毒症患者的病死率仍居高不下。为帮助临床医生更好处理脓毒症和脓毒性休克病患,梅斯小编整理了英文版、中文版及解读版的脓毒症和脓毒性休克管理指南,供大家参考! 一、2016 拯救脓毒运动: